This map shows the geographic impact of PE Postmus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by PE Postmus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites PE Postmus more than expected).
This network shows the impact of papers produced by PE Postmus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by PE Postmus. The network helps show where PE Postmus may publish in the future.
Co-authorship network of co-authors of PE Postmus
This figure shows the co-authorship network connecting the top 25 collaborators of PE Postmus.
A scholar is included among the top collaborators of PE Postmus based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with PE Postmus. PE Postmus is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Postmus, PE & Egbert F. Smit. (1998). Small-cell lung cancer: is there a standard therapy?. PubMed. 12(1 Suppl 2). 25–30.6 indexed citations
3.
Giaccone, Giuseppe, PE Postmus, Nico van Zandwijk, et al.. (1997). Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer.. PubMed. 11(4 Suppl 3). 11–4.6 indexed citations
Postmus, PE, et al.. (1996). Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group.. PubMed. 23(5 Suppl 12). 10–3.20 indexed citations
Withoff, Sebo, Egbert F. Smit, Anke van den Berg, et al.. (1994). Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.. PubMed. 71(1). 61–6.9 indexed citations
8.
Postmus, PE, et al.. (1994). [Treatment of spontaneous pneumothorax: survey among Dutch pneumonologists].. PubMed. 138(13). 661–4.3 indexed citations
Vries, Elisabeth G.E. de, G Mesander, NH Mulder, et al.. (1988). Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up.. PubMed. 48(23). 6891–9.74 indexed citations
13.
Mulder, NH, et al.. (1986). High-dosage chemotherapy with autologous bone marrow reinfusion in the treatment of patients with solid tumours. The Groningen experience, 1981-1986.. PubMed. 29(11). 359–64.4 indexed citations
14.
Postmus, PE, et al.. (1984). High-dose etoposide for refractory malignancies: a phase I study.. PubMed. 68(12). 1471–4.64 indexed citations
15.
Mulder, NH, et al.. (1984). Feasibility of high dose VP 16-213 as single agent or in combination with cyclophosphamide and autologous bone marrow transplantation (ABMT).. PubMed. 27(10). 389–92.2 indexed citations
16.
Klášterský, Jean, et al.. (1983). Complications of treatment of small cell carcinoma of the lung.. PubMed. 67(1). 21–6.21 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.